CLINICAL_TRIALS
trial_result
· 2026-04-23
Clinical Trial Update: Caplyta in Borderline Personality Disorder [Phase 2]
Summary
The Phase 2 trial of Caplyta (lumateperone) for Borderline Personality Disorder has completed and its results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Chicago | Conditions: Borderline Personality Disorder | Phase 2 | Status: COMPLETED | Results posted: 2026-04-23